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ABSTRACT
Introduction: Renal cell carcinoma with sarcomatoid differentiation is a tumor with aggres-
sive behavior that is poorly responsive to immunotherapy. The objective of this study is to report our
experience in the treatment of 15 patients with this tumor.
Materials and Methods: We retrospectively analyzed 15 consecutive cases of renal cell car-
cinoma with sarcomatoid differentiation diagnosed between 1991 and 2003. The clinical presentation
and the pathological stage were assessed, as were the tumor’s pathological features, use of adjuvant
immunotherapy and survival. The study’s primary end-point was to assess survival of these individu-
als.
Results: The sample included 8 women and 7 men with mean age of 63 years (44 - 80);
follow-up ranged from 1 to 100 months (mean 34). Upon presentation, 87% were symptomatic and 4
individuals had metastatic disease. Mean tumor size was 9.5 cm (4 - 24) with the following pathologi-
cal stages: 7% pT1, 7% pT2, 33% pT3, and 53% pT4. The pathological features showed high-grade
tumors with tumoral necrosis in 87% of the lesions and 80% of intratumoral microvascular invasion.
Disease-free and cancer-specific survival rates were 40 and 46% respectively, with 2 cases respond-
ing to adjuvant immunotherapy.
Conclusions: Patients with sarcomatoid tumors of the kidney have a low life expectancy, and
sometimes surgical resection associated with immunotherapy can lead to a long-lasting therapeutic
response.
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INTRODUCTION
Every year, renal cell carcinoma (RCC) is
responsible for approximately 2% of new cases of
cancer in the United States and for the highest pro-
portion of cancer-associated deaths in relation to all
other malignant urological diseases (1).
Initially called carcinosarcoma (2), mixed
renal tumor (3), and subsequently renal sarcomatoid
tumor according to Farrow et al. (4), the sarcomatoid
differentiation is not a distinct histological entity and
confers higher aggressiveness on any of the different
subtypes of RCC, with a frequency ranging from 1 to
8% in the series (4-6). Studies indicate that the pres-
ence of a sarcomatoid component makes the disease
locally aggressive, which typically presents an ad-
vanced grade that is associated with fast progression
and fatal outcome in a vast proportion of cases, with
median survival lower than 1 year in many series (5-
11). This is important for predicting the outcome for
patients undergoing nephrectomy due to RCC, since
11
SARCOMATOID DIFFERENTIATION IN RCC
adjuvant therapy in a certain group of patients with
higher risk of progressive disease can be a reason-
able alternative.
We report our experience with sarcomatoid
RCC after assessing its presentation form, the role of
the pathology, the tumor’s pathological features, the
role of adjuvant immunotherapy and the patient sur-
vival rate.
MATERIALS AND METHODS
We retrospectively assessed 231 patients di-
agnosed with RCC who underwent surgical treatment
at our institution from March 1991 to June 2003. The
study included 15 patients aged from 44 to 80 years
old (mean 63 years) whose pathological examination
of the surgical specimen revealed a sarcomatoid com-
ponent.
For pathological analysis, the specimen is
fixed in formalin, embedded in paraffin, sectioned
and fixed as usual by hematoxylin-eosin (HE). In
addition to sarcomatoid differentiation characterized
by elongation of the tumor cells (Figure-1), we ana-
lyzed the nuclear grade, pleomorphism, mitotic in-
dex and tumoral necrosis. The immunohistochemi-
cal analysis was performed in 8 patients with exclu-
sive sarcomatoid differentiation, confirming the pres-
ence of an epithelial component.
Age, gender and presentation symptoms were
assessed, as well as the stage of the disease, the patho-
logical features, the use of adjuvant immunotherapy,
the time to recurrence of the disease and the survival
of this group of individuals. Postoperative follow-up
was bi-annual through hematological and imaging
exams with ultrasound interpolated with tomography
and chest radiography.
The statistical analysis through survival
curves was performed by the Kaplan-Meier method,
with the log Rank test being used for comparison.
RESULTS
Of the 15 patients under study, the mean age
was 63 years (44 - 80), comprising 8 women and 7
men. Upon presentation, 87% were symptomatic, with
pain, weight loss and hematuria being the most fre-
quent complaints. Additionally, in 4 patients the ini-
tial presentation was metastatic lesion. Table-1 lists
the demographic data of patients under study.
Eight patients had exclusive sarcomatoid dif-
ferentiation, and 7 patients presented association with
clear cell carcinoma (Figure-1).
All patients underwent radical nephrectomy.
One woman who presented recurrence in
retroperitoneum on 3 occasions underwent resection
of the lesion at all times, and has been followed for 6
months now.
Systemic adjuvant treatment was instituted in
2 patients (13.3%). Patient #8, whose initial presenta-
tion was pulmonary metastatic disease, received adju-
vant immunotherapy with interferon and interleukin
with full response and disappearance of the pulmo-
nary nodule, remaining free of the disease in 72 months
of follow-up. Patient #11 received adjuvant dendritic
cell vaccine and is presenting a good performance sta-
tus after 56 months of follow-up despite having under-
gone 3 resections of retroperitoneal masses with patho-
logical diagnosis of sarcomatoid RCC and being sub-
mitted to new vaccine applications.
Cancer-specific and disease-free survival
curves are represented in Figures-2 and 3, respec-
tively. Mean time to recurrence of the disease was 30
months. Among the total of 8 deaths, 7 were due to
progression of the disease within a mean period of
Figure 1 – Photomicrography of sarcomatoid differentiation in
clear renal cell carcinoma.
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17.2 months (4 - 40). A 66-year man (#12) with a
stage T3cN2M0 tumor who underwent radical nephre-
ctomy by thoracophrenolaparotomy, died as a conse-
quence of pulmonary embolism on the 30th postop-
erative day.
We observed that 80% of the surgical speci-
mens had microvascular invasion, 87% were tumors
with high Fuhrman’s nuclear grade. Two individuals
(14%) had localized disease (stage I and II), 33% stage
III, and 53% stage IV.
COMMENTS
Our work showed that RCC with sarcoma-
toid differentiation presents an advanced stage and is
symptomatic in 87% of cases, with a mean tumor size
of 9.5 cm, with high Fuhrman’s nuclear grade, and
life expectancy of 40% within 3 years.
There is controversy as to whether the amount
of sarcomatoid tumor is relevant when analyzing the
disease’s potential for recurrence. In the present se-
ries, there is similarity concerning the clinical pre-
sentation and the outcome of individuals with pure
sarcomatoid tumors compared with tumors associated
with clear cell carcinoma. However, when there is
more than 50% of this component, survival is worse
(6,9), which is contested by Bertoni et al. (8). Never-
theless, the same author states that only individuals
with low Fuhrman’s nuclear grade tumors and less
than 5% of sarcomatoid component have real chances
of cure. The frequency of sarcomatoid tumors with
high Fuhrman’s nuclear grade is 64 - 100% (6,9,12),
and in our series, 87 % of tumors presented this char-
acteristic.
Some evidence suggests that the sarcomatoid
tumor is most often associated with chromophobe
RCC (6); however, the histological type does not in-
fluence the disease’s outcome (6,9,11). In our sample,
we did not identify any chromophobe RCC, and the
clear cell subtype was identified in half the cases.
Cheville et al. (12) explain the median sur-
vival of 8 months in their series as resulting from
advanced stage, tumor size and presence of necrosis,
with the same significance attributed by Frank et al.
(13). Additionally, the presence of necrosis promotes
a relative risk of 3.35 (12). For the studied group, in
87% of cases there was tumoral necrosis.
The fact that these tumors are symptomatic
in 86 to 89% of cases (11,12) and the identification
of advanced stage in two-thirds of the cases present-
ing voluminous tumors explains their aggressiveness
potential. Table-2 displays several studies on sarco-
matoid RCC, facilitating a comparative analysis with
the present series and confirming the invasive profile
of the disease. In our sample, the predominant symp-
toms were hematuria, pain and emaciation in 75% of
Figure 2 – Cancer specific survival. Figure 3 –  Disease-free survival.
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patients, with diagnosis being incidental in only 2
individuals. On the other hand, 4 patients (26,6%)
had metastatic disease at the time of surgery.
Patients with sarcomatoid RCC have a mean
survival of 49.7 months for pT1 stage and 6.8 months
for pT2 - pT4 stages (9,14). Other series present glo-
bal survival lower than 1 year (5-11).
Surgical resection only, does not significantly
change the disease’s clinical outcome since the ma-
jority of these tumors is metastatic or locally advanced
at the moment of diagnosis, with a very short sur-
vival rates for these patients regardless of the type of
treatment (3-5,7,11,15). If left untreated, the sarco-
matoid RCC leads to death within a period of 3.8 to
6.8 months (4,7). The potential for aggressiveness of
such tumors is highlighted by Cangiano et al. (10),
who identified in their series 84% of metastases at
the moment of surgery. Despite controversies con-
cerning the responsiveness of sarcomatoid RCC to
chemotherapy and immunotherapy, (7,10) we had
satisfactory responses with dendritic cell vaccine in
1 case – a woman who presented a recurrence in the
renal cavity and underwent resection of the retro-
peritoneal mass at 3 occasions with adjuvant vac-
cine – and who currently has an optimal performance
status with 56 months of follow-up. In another pa-
tient who received interleukin and interferon adju-
vant to nephrectomy, the pulmonary metastatic le-
sion disappeared and she is alive and disease-free
72 months after surgery. One individual who under-
went resection of a trochanteric bone lesion follow-
ing a pathological fracture and whose specimen re-
vealed metastatic RCC, underwent radical nephrec-
tomy and subsequently femoral radiotherapy, and has
been free of disease for 36 months now. The best
results for regression of metastases with immuno-
therapy reach 31% in 3 years (16); moreover, the
rate of full remission with interferon and interleukin-
2 as monotherapy is 15 to 20% (17), which are dis-
couraging responses.
As a future perspective, we should consider
the possibility of adjuvant therapy for high-risk dis-
eases such as renal sarcomatoid tumors since this
treatment is recommended even for localized disease
due to the extremely low morbidity of the autologous
renal tumor cell vaccine (18).
Individuals diagnosed with RCC with sarco-
matoid differentiation present a serious disease with
reserved prognosis; however, adjuvant immuno-
therapy can improve the outcome of some individu-
als.
________________________________________
Adriana Sañudo performed the statistical analysis.
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